Suggested remit: To appraise the clinical and cost effectiveness of oxybutynin hydrochloride (Vesoxx) within its marketing authorisation for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Technology proceeding to scope development.
- Process:
- TA
- ID number:
- 5089
Project Team
- Project lead
- Michelle Adhemar
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 August 2022 (10:00) | Scoping workshop |
| 07 July 2022 - 04 August 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 July 2022 | In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual